Based on results from the EFFISAYIL™ 2 trial, which met its primary and key secondary endpoints for the prevention of generalized pustular psoriasis (GPP) flares1,2,3 Designation granted in recognitio
Boehringer Ingelheim and 3T Biosciences, today announced they have entered into a strategic collaboration and licensing agreement to discover and develop next-generation cancer therapies to address hi
Paola Casarosa appointed member of the Board of Managing Directors per July 1, 2023, with responsibility for the Innovation Unit per January 1, 2024. Shashank Deshpande appointed member of the Board o
Boehringer Ingelheim and Click Therapeutics today announced the launch of an expanded collaboration for the development and commercialization of a second prescription-based digital therapeutic (PDT).
Spesolimab is a monoclonal antibody that inhibits interleukin-36 (IL-36) signaling and is the first treatment specifically approved for the treatment of generalized pustular psoriasis flares After on
InPedILD Phase III trial showed encouraging results for both primary endpoints. Full data were published in the European Respiratory Journal and presented at the European Respiratory Society Internati
/newsonfloor/media/post_banners/6x1Mny7NhmDQ804kq1KA.jpg)
/newsonfloor/media/post_banners/UakXbbqU4Urakb5vrLLk.jpg)
/newsonfloor/media/post_banners/UDUYX3mcjpkGr7iGDaJ1.jpg)
/newsonfloor/media/post_banners/Uot3PodfUQlAik1Iayo4.jpg)
/newsonfloor/media/post_banners/NNS1DhGri8ept5B4AoHI.jpg)
/newsonfloor/media/post_banners/eyxAKVoKOh5OyMe5KWEv.jpg)
/newsonfloor/media/post_banners/Ko2l3KGxd3YdrgiORIHS.jpg)
/newsonfloor/media/post_banners/2NUQWRZpFXJrCwkm3TYW.jpg)
